Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma

The CheckMate 066 trial investigated nivolumab monotherapy as first-line treatment for patients with previously untreated BRAF wild-type advanced melanoma. Five-year results are presented herein. PATIENTS AND METHODS: In this multicenter, double-blind, phase III study, 418 patients with previously u...

Full description

Saved in:
Bibliographic Details
Published in:J Clin Oncol
Main Authors: Robert, Caroline, Long, Georgina V., Brady, Benjamin, Dutriaux, Caroline, Di Giacomo, Anna Maria, Mortier, Laurent, Rutkowski, Piotr, Hassel, Jessica C., McNeil, Catriona M., Kalinka, Ewa Anna, Lebbé, Céleste, Charles, Julie, Hernberg, Micaela M., Savage, Kerry J., Chiarion-Sileni, Vanna, Mihalcioiu, Catalin, Mauch, Cornelia, Arance, Ana, Cognetti, Francesco, Ny, Lars, Schmidt, Henrik, Schadendorf, Dirk, Gogas, Helen, Zoco, Jesús, Re, Sandra, Ascierto, Paolo A., Atkinson, Victoria
Format: Artigo
Language:Inglês
Published: American Society of Clinical Oncology 2020
Subjects:
Original Reports
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7676881/
https://ncbi.nlm.nih.gov/pubmed/32997575
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.00995
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items